Most consumer categories have seen uptick in demand in the ongoing festive season. We believe volume growth trajectory has bottomed out. However, we don't expect HUL's volume growth to accelerate meaningfully (high single digit territory) in 2HFY20 given its higher base on a 3 year CAGR basis (9% vs. 6% in 1HFY20). GSK's acquisition is running behind schedule and is expected to be integrated by Feb-20 (vs. Dec-19 earlier). We maintain our NEUTRAL rating as we don't see any near-term triggers for re-rating in the stock. HULs 2QFY20 show was respectable amidst concerns of slowdown worsening. Co maintains a cautious outlook and hopes for a recovery in rural demand. We maintain our estimates and NEUTRAL rating. We value HUL at 45x on Sep-21 EPS with TP of Rs 2,017.